$14.07

-0.36 (-2.49%)

7/18/2008 4:00 PM

Albany Molecular Research, Inc. (AMRI)

CAPS Rating:

The Company is a global chemistry-based drug discovery and development company focused on identifying and developing novel biologically active small molecules with applications in the drug market.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other players to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating AMRI

Add Stock to Watchlist

What the Community Thinks

Total Players

53 Outperforms

6 Underperforms

All-Stars

24 Outperforms

2 Underperforms

Wall Street

1 Outperforms

1 Underperforms

Players bullish on AMRI are also bullish on:

Players bearish on AMRI are also bearish on:

Ticker Tags

Research Services (46), Micro Cap (4824)
Suggest a tag

Albany Molecular Research, Inc. At A Glance

Current Price:	$14.07
Last Trade Time:	7/18/2008 4:00 PM
Open:	$14.37
Previous Close:	$14.43
Daily Range:	$13.93 - $14.82
52-Week Range:	$9.25 - $19.05
Volume:	127,875
Market Cap:	$457.81M
P/E Ratio:	43.73
Compare Our Special Broker Offers!

Stock Trends

AMRI VS S&P 500 (SPY)

News & Discussion Boards

Other News Headlines for AMRI

Albany Molecular shares jump after 1Q profit rises
5/5/2008 5:55:00 PM - AP
Movers roundup: Albany Molecular Research, PMA Capital
5/5/2008 3:15:00 PM - AP
Albany Molecular Rebounds After Earnings
2/12/2008 6:35:00 PM - AP
Movers Roundup: BioMarin Pharma, Dyax
2/12/2008 6:20:00 PM - AP

More Headlines...

Top Bull Pitch

Recs

1 Albany Molecular Research, Inc. (AMRI)

Avatar NeroSagetrade (90.13) Submitted: 10/09/07 11:05 PM

Albany Molecular Research is another case of the slow and steady turtle executing with a solid management team to deliver results. The past four quarters have shown rather large earnings beats and at 31 times earnings and with $3.14 per share in cash I think they can solidly deliver 15% stock price ...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Players

Show Me:

Sort by:

picks per page. CHANGE

Results 1 - 5 of 11 : 1 2 3 Next »

Recs 0 (AMRI) ResearchLover (95.13) Submitted: 5/14/08 5:44 PM : Start Price: $14.01 AMRI Score: 11.15 I like the CRO (contract research organization) sector right now. In addition AMRI tries to do some R&D in house and thus has it's own pipeline available for partnered development beyond phase I. That promises to be a good mix. Their targets (tubulin, orexigenic peptide receptor, serotonin reuptake) aren't that novel, but they successful development of compounds is likely to demand some to much market share of some pretty large markets (cancer, obesity, depression). Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (AMRI) equalfuture (46.60) Submitted: 4/10/08 4:52 AM : Start Price: $11.74 AMRI Score: 26.75 BUYING AT 5 PER SHARE, stock is valued in my fair value estimates at 5.40 a share i expect movement at this price in late summer. good company worth 5 or more a share. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (AMRI) samlove (97.98) Submitted: 1/02/08 1:52 PM : Start Price: $13.70 AMRI Score: 15.57 On a strictly technical basis, my magic charts say this will outperform the S&P Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (AMRI) unclestalin (79.75) Submitted: 11/08/07 11:17 AM : Start Price: $11.67 AMRI Score: 35.11 total risky pick here. But I live close to albany molecular, and they are a big deal in town. granted it's albany ny though. I have seen them working on stuff, their head honchos are decent people and their workers are all high quality. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 1 (AMRI) NeroSagetrade (90.13) Submitted: 10/09/07 11:05 PM : Start Price: $16.83 AMRI Score: 2.82 Albany Molecular Research is another case of the slow and steady turtle executing with a solid management team to deliver results. The past four quarters have shown rather large earnings beats and at 31 times earnings and with $3.14 per share in cash I think they can solidly deliver 15% stock price appreciation per annum. The price to book valuation is in-line if not just below the sector average and the long-term technicals show an ascending triangle that wants to break hgiher above $18. All signs pointing higher. Nero Sagetrade Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Results 1 - 5 of 11 : 1 2 3 Next »

Wall Street

Results 1 - 2 of 2

picks per page. CHANGE Expand All Pitches Collapse All Pitches

Top Pick	Player Name	Player Rating	Start Date	Call	Time Frame	Start Price	Stock Gain	S&P Gain	Score	Pitch
	TrackJimCramer	82.55	01/24/08 01/24/08		3W	$13.21	+6.51%	-6.62%	-13.13
	TrackSoros	86.22	09/30/07 09/30/07		NS	$15.10	-6.82%	-17.39%	+10.57

Results 1 - 2 of 2

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.